{
    "organizations": [],
    "uuid": "41fdb554bb8f2049d93faa43fa5ef8537cc0b913",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sanuwave-receives-fda-de-novo-deci/brief-sanuwave-receives-fda-de-novo-decision-to-immediately-market-dermapace-system-for-treatment-of-diabetic-foot-ulcers-in-u-s-idUSFWN1OX07U",
    "ord_in_thread": 0,
    "title": "BRIEF-Sanuwave Receives FDA De Novo Decision To Immediately Market Dermapace System For Treatment Of Diabetic Foot Ulcers In U.S.",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "#Market News  14 PM / Updated 8 minutes ago BRIEF-Sanuwave Receives FDA De Novo Decision To Immediately Market Dermapace System For Treatment Of Diabetic Foot Ulcers In U.S. Reuters Staff 1 Min Read \nJan 2 (Reuters) - Sanuwave Health Inc: \n* SANUWAVE RECEIVES FDA DE NOVO DECISION TO IMMEDIATELY MARKET THE DERMAPACE SYSTEM FOR THE TREATMENT OF DIABETIC FOOT ULCERS IN THE U.S. Source text for Eikon: Further company coverage:",
    "published": "2018-01-02T15:12:00.000+02:00",
    "crawled": "2018-01-02T15:28:25.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "pm",
        "updated",
        "minute",
        "ago",
        "receives",
        "fda",
        "de",
        "novo",
        "decision",
        "immediately",
        "market",
        "dermapace",
        "system",
        "treatment",
        "diabetic",
        "foot",
        "ulcer",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "sanuwave",
        "health",
        "inc",
        "sanuwave",
        "receives",
        "fda",
        "de",
        "novo",
        "decision",
        "immediately",
        "market",
        "dermapace",
        "system",
        "treatment",
        "diabetic",
        "foot",
        "ulcer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}